Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo.
At close: January 21 at 4:00:02 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback